Merry Christmas and a Happy New Year 2023
The year 2022 is coming to an end – a good opportunity to look back once again.
Continue readingThe year 2022 is coming to an end – a good opportunity to look back once again.
Continue readingWhat exactly are immunoglobulins, why do we need them and why are they reduced in some people by the so-called B-cell depleters Ocrelizumab and Ofatumumab? Do you always have to take action with low immunoglobulin
Continue readingWhat to do when immunoglobulin levels are lowered by B-cell depletion? – In the first post on this topic, I outlined how important B-cell-depleting therapies are for the treatment and stabilization of especially (highly) active
Continue readingB-cell depleting therapies such as Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta) or the newly approved Inebilizumab (Uplizna) for the treatment of NMOSD are currently very important tools for controlling active MS courses and for preventing relapses in
Continue readingOptic neuritis (inflammation of the optic nerve) is often the first symptom of multiple sclerosis and thus the start of targeted diagnostics and often also the starting point of a specific immunotherapy. Therefore, it is
Continue readingAutologous hematopoietic stem cell transplantation (AHSCT) is a topic of intense interest among patients. To explain briefly again: Autologous hematopoietic stem cell transplantation (AHSCT) is not about replacement or repair of nerve tissue. This possibility
Continue readingIn view of practically relevant results from this year’s ECTRIMS meeting, I would like to emphasize studies on pregnancy and breastfeeding. B-cell-depleting therapies such as ocrelizumab and ofatumumab are often used in women of childbearing
Continue readingFinally back in person! After the meeting of the European Committee for Therapy and Research in Multiple Sclerosis (ECTRIMS) was held virtually due to the pandemic over the last two years, MS experts from all
Continue readingBruton tyrosine kinase inhibitors, or BTKi for short, are by no means new. They are known from cancer therapy and have been adapted for the treatment of neurologically degenerative diseases. So, will there soon be
Continue readingWhile there have been frequent updates about long-term immunotherapy for MS recently, the approach to treating MS relapses has remained unchanged for years. The treatment of acute MS relapses typically involves a high-dose corticosteroid preparation
Continue readingUnsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.